{
  "text": "Abstract\nAxicabtagene ciloleucel (axi-cel) is an autologous chimeric\nantigen receptor (CAR) T-cell therapy approved for adults with | Progression-Free Survival Overall Survival\nrelapsed/refractory (R/R) large B-cell lymphoma (LBCL) after 21 prior Adult patients with R/R LBCL treated with axi-cel with 100 i Outpatient 100-+sxy rn C 4 1007\u2014wpam OO sc 4\nline of therapy\"? 21 prior line of therapy between July 2021-November 2023 0 0 i ome\" eieels\n; ; re ; Beane _\u2014\u2014 83% 83% Inpatient *\nIn the pivotal ...",
  "full_text_length": 12494,
  "processing_time": 25.35393500002101,
  "word_count": 2126,
  "char_count": 12494,
  "confidence": 0.8355357142857143,
  "metadata": {
    "engine": "Tesseract",
    "lang": "eng",
    "config": "--psm 6",
    "total_words": 2126,
    "avg_confidence": 83.55357142857143,
    "min_confidence": 1,
    "max_confidence": 97,
    "image_shape": [
      3500,
      6000,
      3
    ],
    "preprocessing_applied": false
  },
  "errors": [],
  "model_name": "Tesseract",
  "timestamp": "2025-10-29T14:50:25.075379",
  "memory_usage_mb": 61.83971881866455,
  "file_hash": "accee7faf11226aca5ec083b7c827520",
  "chars_per_second": 492.78346733907955
}